Hansa Biopharma AB (publ) (HNSA.ST)
Develops antibody-cleaving medicines to help transplant and autoimmune disease patients.
36.88-0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+29.5%
The outlook
HNSA.ST is trading at 36.88, positioned solidly above its 50- and 200-day moving averages and roughly two-thirds of the way up its 52-week range. Analyst consensus leans strongly positive, with an average target implying roughly 98% upside from current levels. The overall data picture reflects bullish positioning in both technicals and analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range66% of the way from its 52-week low to high
Price targetAvg target +98% vs current price
Analyst price target
~12-month · 8 analysts73.00average target+97.9% vs now
Now 36.88
Low 36.00High 103.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.68B
52-wk high
43.80
52-wk low
23.52
50-day avg
33.41
200-day avg
32.08
Trailing P/E
—